Peptide API Manufacturing: AI Visibility Market Discovery Index

Benchmark Summary

Bachem leads the Peptide API Manufacturing benchmark in October 2026 with valid recommendation coverage of 67.0%, up from 42.2% in July 2026. The gap to the next brand stood at 44.5 percentage points over AmbioPharm, which held 22.5% coverage in October 2026, up from 21.8% in July 2026. The largest coverage increase beyond normal month-to-month variation belonged to Bachem, rising from 36.2% in September 2026 to 67.0% in October 2026. No brand registered a coverage decline beyond normal variation across the series.

Across the full series, Bachem has held the leadership position in all four months, with valid recommendation coverage of 42.2% in July 2026, 44.8% in August 2026, 36.2% in September 2026, and 67.0% in October 2026. Five brands held stable classifications across the baseline-to-current series, while CSBio moved down in each of the three months since July 2026. The benchmark began with 306 prompt-surface observations in October 2026 and produced 200 qualified observations after qualification.

Current Benchmark at a Glance

Qualified surface breadth counts the canonical AI/search surface families with at least one qualified observation, rolling keyword variants into their parent families. The six canonical families are ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.

For the strategic interpretation of this benchmark, read CiteWorks Studio's analysis of How AI Search Is Recommending Peptide API Manufacturing

Research Scope and Qualification

The public benchmark is narrower than the raw collection universe by design.

Brand-level percentages use the qualified observations as the public denominator, not the raw collection. See AI Market Discovery Methodology.

Current Brand Standings

Questions This Section Answers

• Which peptide API brands lead on valid recommendation coverage in October 2026?
• How do the leading brands differ on top-three placement and rank-one recommendation rates?

How to Read the Standings

Presence rate is the share of qualified observations in which the brand is mentioned at all. Valid recommendation coverage is the share of qualified observations in which the brand receives a valid recommendation. Top-three rate is the share of qualified observations in which the brand appears in the first three recommended positions. Rank-one rate is the share of qualified observations in which the brand is the first recommendation. Net sentiment is the balance of positive over negative mentions among observations where the brand is present.

For formulas and denominator rules, see AI Market Discovery Metric Definitions.

Recommendation Coverage Movement

Questions This Section Answers

• Which peptide API brands posted recommendation coverage gains beyond normal variation in October 2026?
• How far did Bachem's coverage lead over the second-place brand widen since July 2026?

October 2026 brought the widest movement of the series. Five brands posted gains beyond normal variation from September 2026 to October 2026: Bachem, AmbioPharm, PolyPeptide Group, CPC Scientific, and CordenPharma Peptides.

Largest Increase: Bachem

Bachem rose to 67.0% valid recommendation coverage in October 2026, up from 42.2% in July 2026 and up from 36.2% in September 2026. The move beyond normal variation was the largest single-month change in the series. Its top-three rate rose from 35.6% in July 2026 to 60.5% in October 2026, and its rank-one rate rose from 22.2% to 44.0% over the same period. Presence rate moved from 91.1% to 92.5%.

Category Leader: Bachem

Bachem held the leadership position in all four months, with valid recommendation coverage of 42.2% in July 2026, 44.8% in August 2026, 36.2% in September 2026, and 67.0% in October 2026. The gap over the second-place brand widened from 20.4 percentage points in July 2026 to 44.5 percentage points in October 2026, expanding in each month of the series.

Stable brands formed a middle cluster. PolyPeptide Group rose from 9.8% in July 2026 to 14.5% in October 2026, CPC Scientific rose from 7.6% to 13.0%, AmbioPharm held near its baseline at 22.5%, and CordenPharma Peptides rose from 3.6% to 7.5%. Biosynth Peptide Division declined slightly from 12.4% to 11.0%, a move within normal variation. CSBio, classified as a watch item, declined in each of the three months since July 2026, from 3.1% to 1.0%, with a cumulative change that remains within normal variation.

Recommendation Placement Snapshot

Questions This Section Answers

• How did Bachem and AmbioPharm differ on first-position recommendations in October 2026?
• Can similar recommendation coverage still hide different rank-one placement rates?

Coverage alone does not show how prominently a brand is recommended. Among the leading cluster of Bachem and AmbioPharm, placement patterns diverged in October 2026.

Close coverage can still hide different first-position rates. Bachem's rank-one rate of 44.0% in October 2026 was well above AmbioPharm's 2.0%, even though the two brands sat 44.5 percentage points apart on coverage.

Buyer-Intent Distribution

Questions This Section Answers

• Which buyer-intent classes produced qualified observations in the benchmark?
• Are Pricing & Value or Multi-Brand Comparison observations included in the current series?

All qualified observations in both months fell into the Brand Recommendation class of discovery.

The current public series measures the Brand Recommendation class of discovery and does not yet contain qualified observations in the Pricing & Value or Multi-Brand Comparison classes.

Historical Measurement Record

Questions This Section Answers

• What does the measurement record show about Bachem's coverage leadership across the series?
• Which single measurement saw the largest coverage movement, and by how much?

This is an evergreen benchmark URL. New measurements are added to the same report.

Top 10 Cited Domains

Questions This Section Answers

• Which domains were cited most often across AI platform responses in October 2026?
• Which tracked peptide API brand domains appeared in the top 10 cited sources?

Across all AI platform responses in October 2026, 2,146 citations were observed across 564 unique domains. The most-cited sources were as follows.

Citations are broadly distributed. The top 10 domains account for roughly 35% of all citations, with the remaining share spread across more than 550 domains, suggesting no single source dominates the information environment. Two tracked brands appear in the top 10: bachem.com at rank one and ambiopharm.com at rank eight. Official brand domains, social and community platforms, and third-party peptide-focused sites all appear, indicating that recommendation context draws from a mix of manufacturer-owned, user-generated, and specialist sources.

Evidence and Source Layer

The benchmark is built from prompt-level observations that retain the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources. Source presence is evidence about the information environment. It is not automatically proof that the source caused the recommendation.

Scope Boundaries

This public benchmark does not measure market share, attributable sales, every possible AI response, organic-search ranking, social mention volume, private or sponsored channels, or causality from a metric movement alone. It tracks how AI-powered discovery surfaces present brands within the Peptide API Manufacturing category, based on the qualified observation set defined above.

About This Benchmark

The LLM Authority Index AI Market Discovery Index tracks how AI-powered discovery surfaces present brands within a vertical, measuring presence, recommendation coverage, placement, and sentiment across six canonical AI/search surface families. The benchmark is updated monthly with a consistent methodology.

• AI Market Discovery Methodology
• AI Market Discovery Metric Definitions
• AI Market Discovery Research Standards
• Modeled AI Authority Value

Get a Company-Level Authority Index

The public industry benchmark shows category-level standings. A company-level Authority Index can go deeper.

Get my free AI Company Index